SEC Tracker
Get the app

Renovaro LNAI

Renovaro Q2 FY25: net loss $7.3M; diluted EPS −$0.04

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q
Exhibit 10.2
Material contract
Exhibit 10.3
Material contract

Key figures from this report

These are the numbers Renovaro reported for Q2 FY25, the quarter ended Dec 31, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$7.3MAgainst −$4.5M in Q2 FY2410-Q income statement, on EDGAR
  2. Diluted EPS−$0.04Against −$0.07 in Q2 FY2410-Q income statement, on EDGAR
  3. Cash and cash equivalents$312K+28% from $244K in Q2 FY2410-Q balance sheet, on EDGAR
  4. Cash from operations−$2.6MAgainst −$3.1M in Q2 FY2410-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Renovaro files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Dare Bioscience DARE public float $21M, Jun 30, 2025
  2. Imunon IMNN public float $21M, Jun 30, 2025
  3. Armata Pharmaceuticals ARMP public float $21M, Jun 30, 2025
  4. Fibrogen FGEN public float $21M, Jun 30, 2025
  5. Aptose Biosciences APTOF public float $22M, Jun 28, 2025